Seer, Inc. to Showcase Proteograph Product Suite at ASHG 2024 Annual Meeting

REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company, will showcase its Proteograph Product Suite at the American Society of Human Genetics (ASHG) 2024 Annual Meeting in Denver, Colo., from Nov. 5-9. The suite's unique ability to deliver deep proteomic insights complements and strengthens genomic and other "omic" research.

Seer will present a CoLab session exploring research breakthroughs from PrognomiQ and Salk Institute, in addition to several presentations in the scientific sessions enabled by the industry-leading capabilities of Seer's Proteograph Product Suite. Key topics include:

• Lung cancer
• Alzheimer's Disease
• Relative Energy Deficiency in Sport (REDs)

These sessions will explore how Seer links proteomic capabilities with genomic data, producing advanced research at new depths, scales, and speeds.

"Advancements in genomic research in recent decades have significantly enhanced our understanding of biology and human health," said Asim Siddiqui, PhD, Senior Vice President, Research and Tech Development at Seer. "With the Proteograph Product Suite, we are pushing the boundaries of biological insight and opening new frontiers in scientific discovery."

Seer CoLab Session at ASHG 2024:

The Power of Deep Proteomics: Driving the Next Generation of Genomic Research

Unleashing the Power of Multi-omics: A Breakthrough in the Early Detection of Lung Cancer

Philip Ma, PhD
CEO & Founder, PrognomiQ, Inc.

Lung cancer remains a leading cause of death globally, driven by detection at advanced stages. Early detection improves outcomes, but current methods have limitations. Philip Ma and colleagues are developing a multi-omics biomarker test using proteomics, transcriptomics, and metabolomics for early-stage lung cancer detection.

Their MOSAIC study identified biomarkers to accurately discriminate between lung cancer patients and controls. This multi-omics classifier outperformed existing studies, offering a more sensitive and specific approach to lung cancer detection.

"To truly make a difference for the millions of lung cancer patients, we must detect the disease sooner," said Philip Ma, CEO of PrognomiQ. "The work we're doing with Seer's Proteograph platform gives us real hope that more lives can be saved."

Mouse Model of Relative Energy Deficiency in Sport

Laura van Rosmalen, PhD
Satchidananda Panda Lab, Salk Institute for Biological Studies

Relative Energy Deficiency in Sport (REDs) is associated with systemic abnormalities affecting health and performance, but little is known about its molecular impacts. Deep proteomic insights are revealing protein signatures of REDs, with implications for metabolic health and athletic performance.

"A multi-omics approach is essential for understanding REDs," said Satchidananda Panda, PhD. "Seer's technology allows us to understand REDs on a cellular and molecular level, potentially leading to diagnostic tests and therapies."

Highlights from Seer and Collaborators at ASHG 2024:

• Title: A Genome-wide Association Study of Mass Spectrometry Proteomics Using the Seer Proteograph Platform
  Presenting Author: Serafim Batzoglou, PhD
  Date & Time: Nov. 6, 2:30 - 4:30 p.m.
• Title: Understanding the Impact of Genetic Variants on Alzheimer's Disease With Mass Spectrometry Proteogenomics
  Presenting Author: Harendra Guturu, PhD
  Date & Time: Nov. 7, 2:30 - 4:30 p.m.
• Title: Multi-omic Profiling in a 61-day Pig Kidney to Human Decedent Xenotransplant Reveals a Concerted Acute Rejection Immune Response
  Presenting Author: Brendan Keating, PhD
  Date & Time: Nov. 6, 11:15 a.m.

About Seer:

Seer is a life sciences company developing transformative products that open a new gateway to the proteome. The Proteograph Product Suite includes proprietary engineered nanoparticles for deep, unbiased proteomic analysis at scale. The product is for research use only and is not intended for diagnostic procedures.

For more information, visit booth #335 or contact us at pr@seer.bio.

Contacts:

Media Contact:
Patrick Schmidt
pr@seer.bio

Investor Contact:
Carrie Mendivil
investor@seer.bio